Clients

Take a look at our work and the interviews that show how we help our clients grow. The Lavery Signature is our commitment to a strategic partnership where we put your success first. 

  1. Lavery assists Agile MV Inc. in the sale of all of its shares to Resonetics

    On June 13, 2022, Resonetics announced the purchase of the entirety of the shares of Agile MV, a Montréal-based medical device design and development contract manufacturing company. The transaction was motivated by the quality of expertise that Agile MV's team of engineers, scientists, and technicians possess throughout the entire production cycle, from initial concept consolidation to mass production. Our partner, Audrey Gibeault, had the privilege of representing the company in this major transaction that involved complex tax planning, among other things. In business law, this transaction was led by our partner Étienne Brassard. Ms. Gibeault and Mr. Étienne Brassard were mainly assisted in this transaction by Gabrielle Ahélo. They were assisted by Luc Pariseau, Sonia Guérin, France Camille De Mers, Brittany Carson, Éric Gélinas, André Vautour, Michael Pageau, Maxime Chabot and Charles-Hugo Gagné. —Agile MV is a Quebec-based medical device design and development contract manufacturing company. It specializes in the development of minimally invasive diagnostic and therapeutic medical devices in the following areas: cardiac electrophysiology, interventional cardiology, interventional radiology, interventional pulmonology, interventional gastroenterology, interventional pain management and interventional neurology.Resonetics specializes in advanced engineering and manufacturing solutions for the life sciences industry, laser cutting, centerless grinding, nitinol processing, thin-wall stainless steel and precious metal tubing, photochemical machining, microfluidics, sensor solutions and medical energy.

    Read more
  2. Lavery assists Premier Parks LLC in the purchase of Calypso-Valcartier Group’s shares

    On June 2, 2022, Calypso-Valcartier Group announced the sale of all of the shares of its two amusement parks, Village Vacances Valcartier located near Quebec City and Calypso, near Ottawa, and more specifically of the shares of the two parks’ operating corporations and their  asset holding corporations. The assets of the two parks are now indirectly owned by EPR Properties, and they are operated by a Canadian subsidiary of Premier Parks, LLC. Our partners, André Vautour and France Camille De Mers, and their team assisted Premier Parks LLC in the due diligence of the parks’ assets and operations. They participated in structuring the new parks’ operating corporations, in the drafting of the share acquisition documentation of both the asset holding and operating corporations, and in the negotiation of all associated terms. The transaction was realized in collaboration with the Tennessee-based law firm Waller, a member, as is Lavery, of World Services Group, a worldwide network of premier law and other professional firms.

    Read more
  3. Lavery supports Domain Therapeutics in obtaining US $42M in financing

    On May 10, 2022, Domain Therapeutics, a Franco-Canadian biopharmaceutical corporation specializing in research and development of innovative immuno-oncology treatments, announced the close of a US $42 million Series A financing round. This investment is a major step in the Franco-Canadian firm’s growth that aims to provide cancer patients with treatment solutions to overcome GPCR-mediated immunosuppression mechanisms. Mr. Alain Dumont, a partner at Lavery, had the privilege of supporting the corporation through this important transaction. Throughout his long-standing relationship with Domain Therapeutics, Mr. Dumont has lent his expertise to protect the company’s technologies and innovations by answering questions from investors, in particular. Lavery is immensely proud of Mr. Dumont’s work in securing this funding. — Domain Therapeutics, a biopharmaceutical company, based in France and Canada, is dedicated to discovering and developing novel medicine candidates targeting G-protein-coupled receptors (GPCRs), a key drug target class. The company focuses on producing high value-added immuno-oncology drug candidates.

    Read more
  4. Lavery represents ImmunoPrecise Antibodies as it acquires BioStrand

    On March 29, 2022, ImmunoPrecise Antibodies Ltd (IPA) announced that it acquired BioStrand BV, BioKey BV, and BioClue BV (together, “BioStrand”), a group of Belgian entities pioneers in the field of bioinformatics and biotechnology. With this €20 million acquisition, IPA will be able to leverage BioStrand’s revolutionary AI-powered methodology to accelerate the development of therapeutic antibody solutions. In addition to creating synergies with its subsidiaries, IPA expects to develop new markets with this revolutionary technology and strengthen its position as a world leader in biotherapeutics. Lavery was privileged to support IPA in this cross-border transaction by providing specialized expertise in cybersecurity, intellectual property, securities and mergers and acquisitions. The Lavery team was led by Selena Lu (transactional) and included Eric Lavallée (technology and intellectual property), Serge Shahinian (intellectual property), Sébastien Vézina (securities), Catherine Méthot (transactional), Jean-Paul Timothée (securities and transactional), Siddhartha Borissov-Beausoleil (transactional), Mylène Vallières (securities) and Marie-Claude Côté (securities). ImmunoPrecise Antibodies Ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases.

    Read more
1 2 3